What is Nick Hodge’s “Montel’s Miracle” Stock?

Nick Hodge has been focusing a lot on biotech-ish companies for his Early Advantage newsletter lately, and they usually end up being pretty early-stage stocks with good stories about some kind of breakthrough or unique compound or device and no real financials yet (meaning, little to no revenue or earnings) — just the kind of […]